Pharsight

Drugs that contain Nirogacestat Hydrobromide

1. Ogsiveo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951958 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Mar, 2025

(9 months from now)

US7342118 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(1 year, 2 months from now)

US7795447 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(1 year, 2 months from now)

US11845732 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10941118 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10710966 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10590087 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11905255 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11884635 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11884634 SPRINGWORKS Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
Aug, 2039

(15 years from now)

US11820748 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11504354 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(18 years from now)

US11612588 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(18 years from now)

US11807611 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(18 years from now)

US11844780 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(18 years from now)

US11872211 SPRINGWORKS Treatments with nirogacestat
May, 2043

(18 years from now)

US11938116 SPRINGWORKS Treatments with nirogacestat
May, 2043

(18 years from now)

US11925619 SPRINGWORKS Treatments with nirogacestat
May, 2043

(18 years from now)

US11925620 SPRINGWORKS Treatments with nirogacestat
May, 2043

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Nov 27, 2030
New Chemical Entity Exclusivity(NCE) Nov 27, 2028
Orphan Drug Exclusivity(ODE-452) Nov 27, 2030

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET;ORAL

More Information on Dosage

OGSIVEO family patents

Family Patents